Project Grant R21AI189247
Award Date
1/17/25
Completion Date
12/31/26
Dollars Obligated
$223K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Emory University (S352L5PJLMP8)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Georgia, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $145,642 to Emory University to develop virus-like particles (VLPs) for a novel HIV-1 cure strategy. The key objectives are: Using VLPs to deliver the HIV-1 Tat protein as a latency reversing agent, applying a "shock and kill" approach where reactivated latently infected cells are then targeted for...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $474,620 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Regents of the University of California, San Francisco (UCSF) to comprehensively define the selective pressures and evolutionary dynamics of the HIV-1 capsid. The research will utilize a high-throughput saturating mutagenesis approach to measure the fitness effects of all possible single missense mutations in the...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $617,376 to Emory University to conduct research on imaging the protease activation and maturation of single HIV-1 particles. The key objectives are to: 1) measure the timing of HIV-1 protease activation relative to virus scission from the plasma membrane; 2) assess the rate and extent of protease substrate...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $794,005.00 to conduct research on the conformational dynamics and functional consequences of HIV fusion at lipid phase boundaries. The grantee, Georgia Tech Research Corp, will investigate how HIV envelope proteins interact with lipid phase boundaries during the viral fusion process, and the impact of this...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Emory University in the amount of $1,761,680.00. The funding will support research aimed at evaluating the safety and therapeutic potential of a novel combination strategy involving IL-15/IL-15RA therapy and TGF-beta blockade to enhance anti-viral immunity and achieve sustained HIV remission following antiretroviral therapy...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides approximately $697K in funding to conduct research on the epigenetic modification of the HIV-1 RNA cap. The research aims to define the structural basis of HIV cap hypermethylation and its role in viral gene expression and modulation of host immune signaling. The primary awardee is the Regents of the University...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $224,595 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Emory University to develop a self-administered microneedle patch for the long-acting release of antiretroviral agents. The key objectives are to: 1) formulate and optimize the extended release of an antiretroviral agent (islatravir/EFDA) from biodegradable microneedle patches for at least one month, and 2) evaluate the...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA program 93.855 - Allergy and Infectious Diseases Research, supports the development of broadly neutralizing nanobodies for advancing HIV/AIDS therapy. The total award amount is $1,501,625.00 over the period of performance from August 1, 2024 to June 30, 2029. The primary objectives are to identify versatile nanobodies capable of recognizing diverse regions of the HIV...
This federal Project Grant award of $229,163, issued by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the function and trafficking of the HIV-1 envelope (Env) glycoprotein. The research aims to discover new targets for antiviral drug development, which remains critical as the AIDS pandemic continues. The project seeks to test the central hypothesis that a truncated Env...
This federal Project Grant award, issued by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $847,141 to investigate the role of HIV-1 integrase in virion morphogenesis and to explore the use of allosteric integrase inhibitors as a novel therapeutic approach. The primary research aims include: Continuing investigations into the non-catalytic function of HIV-1 integrase during virion morphogenesis,...